NASDAQ:SLP

Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Retrieved on: 
수요일, 5월 22, 2024
Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Apps, Applications, Mobile, Wireless, Simulations Plus, SLP, Biotechnology, Conference

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN.
  • Mr. O’Connor will host one-on-one and small group meetings throughout the day.
  • Each year, Craig-Hallum hosts a multi-industry investor conference featuring more than 130 public companies where institutional clients can meet formally with corporate management.
  • For more information about the conference, please visit the Craig-Hallum conference website .

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Retrieved on: 
수요일, 5월 15, 2024
Consulting, Data Management, Biotechnology, Technology, Professional Services, Health, Public Relations, Investor Relations, Pharmaceutical, Communications, Software, Artificial Intelligence, Science, Algorithm, Simulations Plus, Communication, SLP, Freedom, GPX

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® X .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® X .
  • Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.
  • “GPX is truly a culmination of a long-term collaboration with our partners to understand how we can better support their program needs and enable critical scientific thinking,” said Neil Miller , Vice President of Simulation Sciences at Simulations Plus.
  • “GPX offers increased functionality that other programs cannot provide, such as true polypharmacy simulations mimicking real-world scenarios.

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Retrieved on: 
목요일, 4월 4, 2024
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, Simulations Plus, Pharmacology, QST, Initiative, Partnership, Risk, QSP, SLP, Safety, Toxicology, Liver, Hepatotoxicity, Pharmaceutical industry

Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, said, “It is now known what properties to avoid to minimize liver toxicity in a new drug candidate -- but these same properties are often necessary to have therapeutic efficacy. By predicting safe dosing regimens of such drugs, DILIsym is now enabling successful development of important therapies that might otherwise be abandoned.”

Key Points: 
  • DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI).
  • The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.
  • It also allows the FDA to evaluate the potential DILI risk across multiple populations, which supports informed decision-making regarding drug approvals.
  • Companies interested in a free trial version of the DILIsym software can request it here .

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
수요일, 4월 3, 2024
Science, Software, Research, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Tax, Conference, Forecasting, Conference call, Biophysical environment, EPS, Webcast, ESG, Depreciation, GAAP

The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.

Key Points: 
  • The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
  • To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update .
  • The Company believes that the non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods.
  • Our management also believes that Adjusted EBITDA is useful in evaluating our core operating results.

Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date

Retrieved on: 
수요일, 3월 20, 2024
Software, Research, General Health, Professional Services, Pharmaceutical, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Consulting, Health, Simulations Plus, Webcast, SLP

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.
  • Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results.
  • Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here .
  • The webcast can be accessed on the investor relations page of the Simulations Plus website at www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Retrieved on: 
수요일, 3월 13, 2024
Technology, Health Technology, Software, Biotechnology, Internet, Health, Pharmaceutical, Data Management, Artificial Intelligence, Simulations Plus, SLP, Medtech

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time.
  • In addition, Mr. O’Connor will be meeting one-on-one with investors throughout the day.
  • The live webcast of the Company’s presentation can be accessed via this link and also on the Investors page of the Simulations Plus website where it will be available for replay for approximately 90 days following the event.

Simulations Plus and the University of Bath Awarded New FDA Grant

Retrieved on: 
화요일, 3월 5, 2024
Research, FDA, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Other Science, SLP, Human services, Name, University, Professor, Food, Drug development, Colorado School of Mines, Skin, Government, Simulations Plus, Patient, University of Reading

“Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.

Key Points: 
  • “Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.
  • By doing so, we aim to significantly expedite the regulatory decision-making process, ultimately benefiting patients and the pharmaceutical industry.”
    FDA scientific and program staff will actively collaborate with the University of Bath, Colorado School of Mines, University of Reading, and Simulations Plus.
  • Le Merdy , with assistance from Dr. Jessica Spires and Dr. Jasmina Novakovic at Simulations Plus, will coordinate modeling and simulation activities of the contract.
  • “By combining our expertise with Simulations Plus’ cutting-edge research, we are charting a course towards more efficient drug development and safer healthcare solutions.

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Retrieved on: 
목요일, 2월 15, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, SLP, Environ, Division, Metabolism, Toxicology, Toxicity, North American Menopause Society, Absorption, Biopharmaceutical, Animal, NIEHS, Skin, Risk, Vivo, ADMET, Safety, DTT, Computation, Cheminformatics, Environmental health, Pharmacokinetics, Simulations Plus, Child, Machine learning, Human, Environment, Pharmaceutical industry

“At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.

Key Points: 
  • “At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.
  • “Importantly, these tools are being investigated for their potential to address a critical gap in toxicology research for understanding and modeling human bioactivation of environmental chemicals through xenobiotic metabolism,” Ferguson added.
  • Principal Scientist in the Cheminformatics Solutions team at Simulations Plus.
  • It is the leading physiologically based pharmacokinetic/physiologically based biopharmaceutics modeling (PBPK/PBBM) platform, built and refined over 25 years on the most up-to-date scientific research.

Simulations Plus Launches Corporate Development Initiative

Retrieved on: 
화요일, 2월 13, 2024
Health, Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, SLP, Computational biology, Emerging, Drug design, TAM, Simulations Plus, Chemistry, Research, Investment, Management

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.
  • Simulations Plus will actively pursue investments and partnerships in early-stage technology companies aimed at accelerating software and services innovations, increasing technology leadership in computational biology and chemistry, expanding total market opportunity, and identifying potential M&A candidates.
  • Enhance Innovation and Adoption of Emerging Technologies: Explore software and services innovation and seek deeper visibility into evolving technologies, including artificial intelligence-driven drug design (AIDD) and development.
  • “Our team is very excited to launch this corporate development initiative and formalize our corporate development programs with the flexibility to make strategic investments and form joint partnerships in early-stage companies,” said Will Frederick, Chief Financial Officer and Chief Operating Officer.

Simulations Plus to Participate in Upcoming Healthcare Conferences

Retrieved on: 
화요일, 2월 6, 2024
Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, Digital health, Simulations Plus, SLP, Conference, Cryptocurrency

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
  • The Company will be presenting at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024.
  • For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website .
  • The Company’s slide presentation will be available on the Investors page of the Simulations Plus website.